

Presented by UNC Lineberger Comprehensive Cancer Center

3RD ANNUAL

THOMAS C. SHEA

CLINICAL CANCER

SYMPOSIUM

This year's event focuses on Lymphoma and Chronic Lymphocytic Leukemia, offering insights into current standards of care as well as the most promising emerging therapies poised to advance treatment in the years ahead.

Monday, October 27, 2025
The Umstead Hotel and Spa
100 Woodland Pond Drive, Cary, NC 27513

AGENDA

7:00 - 8:30am	Registration
7:00 - 9:00am	Breakfast
8:30 - 8:45am	Welcome Norman E. Sharpless, MD Professor, Cancer Policy & Innovation UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill School of Medicine

THOMAS C. SHEA, MD (MASTER OF CEREMONIES - MORNING)

8:45 - 9:15am	<i>A Personal Experience in CLL Drug Development</i> John C. Byrd, MD The Gordon and Helen Hughes Taylor Professor and Chair Department of Internal Medicine University of Cincinnati	CLL
9:15 - 9:45am	<i>Modern Frontline Management of CLL</i> Deborah M. Stephens, DO Associate Professor of Medicine Director, CLL & Richter's Program Physician Leader, CLL & Lymphoma Research Program University of North Carolina Chapel Hill	CLL
9:45 - 10:15am	<i>Panel and CLL Cases</i> Moderator Stephens (Byrd, Jensen)	CLL
10:15 - 10:30am	Coffee Break	
10:30 - 11:00am	<i>Can we cure follicular lymphoma?</i> Jonathan W. Friedberg, MD, MMSc Samuel Durand Professor of Medicine Director, James P. Wilmot Cancer Institute University of Rochester	FL
11:00 - 11:30am	<i>Novel Treatment Approaches for Waldenstrom Macroglobulinemia</i> Christopher Dittus, DO, MPH Clinical Director – Lymphoma Program Associate Professor of Medicine Division of Hematology University of North Carolina Chapel Hill	WM
11:30 - 12:00pm	<i>Panel and Indolent Lymphoma Cases</i> Moderator Dittus (Friedberg, Jensen)	
12:00 - 1:00pm	Lunch	

DEBORAH M. STEPHENS, DO (MASTER OF CEREMONIES - AFTERNOON)

1:00 - 1:30pm	<i>Frontline Mantle Cell Lymphoma: Many exciting changes</i> Anne W. Beaven, MD Associate Professor of Medicine Director, Inpatient Clinical Program Vice Chief of Operations Division of Hematology University of North Carolina at Chapel Hill	MCL
1:30 - 2:00pm	<i>Clinical Updates in Hodgkin Lymphoma</i> Boyu Hu, MD Associate Professor of Medicine Director, Lymphoma and CLL Division of Hematology and Hematologic Malignancies University of Utah	HL
2:00 - 2:30pm	<i>Panel and Lymphoma Cases</i> Moderator Shea (Beaven, Grover, Hu, Jensen)	
2:30 - 2:45pm	Coffee Break	
2:45 - 3:15pm	<i>DLBCL: Are precision approaches ready for primetime?</i> Sonali M. Smith, MD Professor of Medicine Chief, Hematology/Oncology Co-Leader, Cancer Service Line University of Chicago	DLBCL
3:15 - 3:45pm	<i>CAR-T Cell Therapy in Lymphoma</i> Natalie S. Grover, MD Associate Professor of Medicine Clinical Director, Cellular Therapy Program Division of Hematology University of North Carolina at Chapel Hill School of Medicine	L/CLL
3:45 - 4:15pm	<i>Bispecific Antibodies for Lymphoma and CLL</i> Mazyar Shadman, MD, MPH Professor and Innovators Network Endowed Chair Medical Director, Cellular Immunotherapy Fred Hutchinson Cancer Center University of Washington	L/CLL
4:15 - 4:45pm	<i>Panel and Aggressive Lymphoma Cases</i> Moderator Smith (Grover, Shadman)	
4:45 - 5:00pm	Closing Remarks	

MASTERS OF CEREMONIES



THOMAS C. SHEA, MD
MORNING



DEBORAH M. STEPHENS, DO
AFTERNOON

WELCOME REMARKS

Norman E. Sharpless, MD

Professor, Cancer Policy & Innovation
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill School of Medicine



Norman “Ned” Sharpless, MD, is a physician, scientist, entrepreneur and former federal official, serving as Director of the National Cancer Institute from 2017 to 2022, and as Acting Commissioner of the US Food and Drug Administration in 2019. Prior to government, Dr. Sharpless was the Wellcome Distinguished Professor of Medicine and Director of the Lineberger Comprehensive Cancer Center at the University of North Carolina School of Medicine. He founded G1 Therapeutics, which developed COSEL-A, an FDA-approved medicine for patients with lung cancer; and is on several for-profit and non-profit boards including Incyclix, Karius Inc, Nucleus Radiopharma, the Eshelman Institute for Innovation, and the American Cancer Society. He is the co-Founder and Managing Director of Jupiter BioVentures, a venture studio that incubates innovative biotech startups in oncology and other disease areas. He is the Professor of Cancer Policy and Innovation at the University of North Carolina School of Medicine, and is a member of the American Association for Cancer Research Academy, the Association of American Physicians, the American Society for Clinical Investigation, and the National Academy of Medicine.

CHAIR, AFTERNOON MC AND SPEAKER

Deborah M. Stephens, DO

Associate Professor of Medicine
Director, CLL & Richter's Program
Physician Leader, CLL & Lymphoma Research Program
University of North Carolina Chapel Hill



Deborah Stephens, DO, has primary research interests that include developing targeted therapies for CLL and lymphoma, studying therapy resistance, and developing supportive therapies for CLL complications. She is principal investigator on multiple clinical trials including the international chair of the SWOG S1925 EVOLVE CLL Study. She leads the CLL Subcommittee within the SWOG Leukemia Working Group and has served on the CLL NCCN Guidelines Panel and the Medical Advisory Board of the CLL Society.

Modern Frontline Management of CLL

PANELIST

Christopher E. Jensen, MD, MSc

Assistant Professor of Medicine
Division of Hematology
University of North Carolina at Chapel Hill



Christopher Jensen, MD, MSc, is an academic hematologist specializing in chronic lymphocytic leukemia, hairy cell leukemia, and lymphoma. His research interests center on geriatric oncology and supportive care. He is committed to understanding the unique challenges older adults face and developing tailored treatment strategies to optimize quality of life. This includes exploring age-specific treatment approaches, integrating palliative care, and identifying supportive care interventions that address the physical, emotional, and social needs of older adults during and after treatment.

SPEAKERS

Anne W. Beaven, MD

Associate Professor of Medicine
Director, Inpatient Clinical Program
Vice Chief of Operations
Division of Hematology
University of North Carolina at Chapel Hill



Anne Beaven, MD, focuses her research on developing CAR-T therapies for patients with lymphoma. She is particularly interested in the management of patients with peripheral T cell lymphoma and cutaneous T cell lymphoma, for which she established a multidisciplinary clinic in conjunction with dermatology.

Frontline Mantle Cell Lymphoma: Many exciting changes

John C. Byrd, MD

The Gordon and Helen Hughes Taylor Professor and Chair
Department of Internal Medicine
University of Cincinnati



John Byrd, MD, is an internationally known researcher and clinical specialist in leukemia and other hematologic malignancies. Byrd is a principal and Chief Medical Officer of Beat AML, an LLC of the Leukemia and Lymphoma Society. He has been part of the successful development of multiple therapeutics in blood cancers, most notably the Bruton's Tyrosine kinase inhibitors (ibrutinib and acalabrutinib). He has over 650 publications, has been continuously funded by the NIH for over two decades, and has received multiple awards for his contribution to the drug development in blood cancers.

A personal experience in CLL Drug Development

Christopher Dittus, DO, MPH

Associate Professor of Medicine
Clinical Director, Lymphoma Program
Division of Hematology
University of North Carolina Chapel Hill



Chris Dittus, DO, MPH, is a clinical researcher specializing in rare subtypes of lymphoma, particularly Waldenstrom Macroglobulinemia (WM). Most recently, he has worked closely with the CAR-T program at UNC to include WM patients on CD19 and Kappa CAR-T trials. He is also part of the WM-NET clinical trial group based at the Dana Farber Cancer Institute and will be opening a trial evaluating epcoritamab for relapsed WM. Dittus recently participated in the 12th International Workshop on WM and is working to expand patient outreach through patient organizations in North Carolina.

Novel Treatment Approaches for Waldenstrom Macroglobulinemia

Jonathan W. Friedberg, MD, MMSc

Samuel Durand Professor of Medicine
Director, James P. Wilmot Cancer Institute
University of Rochester




Jonathan Friedberg, MD, MMSc, has focused his research on the development of novel therapies for patients with lymphoma. He is chair of the lymphoma committee in the SWOG NCTN group and serves as Editor-in-Chief at Journal of Clinical Oncology. He was awarded the Scholar in Clinical Research award from the Leukemia & Lymphoma Society, is a funded investigator from NCI, and has chaired the education program of the American Society of Hematology annual meeting.

Can we cure follicular lymphoma?

Natalie S. Grover, MD

Associate Professor of Medicine
Clinical Director, Cellular Therapy Program
Division of Hematology
University of North Carolina at Chapel Hill

Natalie Grover, MD, has a primary research interest in designing and implementing therapeutic clinical trials in lymphoma and cellular immunotherapy. She is interested in novel approaches based on chimeric antigen receptor T-cell (CAR-T) therapy, including improving the efficacy of current CAR-T approaches, studying new targets and combinations, and management and prevention of unique toxicities associated with therapy.



CAR-T Cell Therapy in Lymphoma

Boyu Hu, MD

Associate Professor of Medicine
Director, Lymphoma and CLL
Division of Hematology and Hematologic Malignancies
University of Utah

Boyu Hu, MD, is a clinical researcher and has been the principal investigator (PI) on over 25 phase I, II and III clinical trials investigating novel treatments and combination therapies for patients diagnosed with lymphoid malignancies and CLL. He is currently the co-chair and national PI for AHOD2131, the NCTN trial seeking to incorporate novel immuno-oncology agents into the treatment landscape for early-stage Hodgkin lymphoma and was a contributing author that led to ANVD treatment regimen becoming the new standard-of-care therapy for advanced stage Hodgkin lymphoma.



Clinical Updates in Hodgkin Lymphoma

Mazyar Shadman, MD, MPH

Professor and Innovators Network Endowed Chair
Medical Director, Cellular Immunotherapy
Fred Hutchinson Cancer Center
University of Washington

Mazyar Shadman, MD, MPH, is a hematologic malignancies expert who specializes in treating patients with lymphoma/CLL. He is involved in clinical trials using novel therapeutic agents, cellular immunotherapy for treatment of lymphoid malignancies. He also studies the clinical outcomes of patients using institutional and collaborative retrospective cohort studies.



Bispecific antibodies in lymphoma and CLL

Sonali M. Smith, MD

Professor of Medicine
Chief, Hematology/Oncology
Co-Leader, Cancer Service Line
University of Chicago

Sonali Smith, MD, has focused her research on improving outcomes for high-risk and vulnerable patients with Hodgkin and non-Hodgkin lymphomas. She has written or co-written dozens of clinical trials and has chaired study sections for multiple foundations and for the NCI. She is the national co-PI of the first prospective trial ever conducted through the NCTN in older patients with diffuse large B-cell lymphoma (S1918), launched in 2021, and serves as senior investigator on several cooperative group clinical trials. She was recently elected to the ASCO Board of Directors.



DLBCL: Are precision approaches ready for primetime?

EXHIBIT HALL

ADC THERAPEUTICS (4)

ASTRAZENECA (8)

BEONE MEDICINES (1)

ELI LILLY AND COMPANY (3)

GENENTECH (6)

GENMAB (2)


JAZZ PHARMACEUTICALS (7)

MERCK & CO., INC. (5)

NOVARTIS INC. (10)

PFIZER (9)

UNC LINEBERGER CTO (11)



UNC Lineberger Cancer Network

Oncology Continuing Professional Education

Learn Anytime, Anywhere!

Live Webinars and Self-Paced, Online Courses



**Advanced
Practice
Provider**



**Patient-
Centered
Care**



**Research
to
Practice**



**Southeastern
American Indian
Cancer Health
Equity Partnership**

Continuing education credits for healthcare professionals

CME - NCPD/CNE - ACPE - ASRT - ODS/CTR

Presented by UNC faculty and other North Carolina
and nationally-known oncology professionals

The latest treatments, clinical trials,
and supportive services available for cancer patients

We also partner with and provide support for over a dozen
organizations within Lineberger Comprehensive Cancer Center

Always Quality Oncology Education!

Always FREE!

Visit the Learning Portal to get started!

learn.unclcn.org

or



**LINEBERGER COMPREHENSIVE
CANCER CENTER**

UNC Lineberger Cancer Network was founded by Thomas C. Shea, MD.



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL



UNC
LINEBERGER

You're cordially invited to the annual
UNC RECEPTION

Saturday, December 6, 2025

7:30-9:30pm

Hyatt Regency Orlando

Room: Celebration 8 (Convention Level)

9801 International Drive

Orlando, FL 32819

Hosted by:

UNC Division of Hematology and the
UNC Lineberger Comprehensive Cancer Center

Reception is being held in conjunction with the ASH annual meeting.

This is NOT an official program of the ASH annual program.

PLEASE RSVP TO MEGAN NOBLE BY NOVEMBER 24th

megan_noble@med.unc.edu

SAVE

THE

DATE

3RD ANNUAL
CHRISTOPHER
PERRI SYMPOSIUM



02.20.2026

Please join us for
topics of high impact
and interest in AML

Scan the QR Code to
register and learn more



Presented by: Atrium Health, Duke Health,
ECU Health, Novant Health, UNC Health

CAROLINA CANCER **CONFAB**



Agenda,
registration
info & vendor
opportunities
to come!

Save the date!

April 10, 11 & 12, 2026
Omni Grove Park Inn, Asheville, NC

Mark your calendars for our 2026 conference dates.

More information about agenda, speakers, registration, room block and vendor opportunities to come.



DR. THOMAS C. SHEA

This annual event has been established to honor Thomas C. Shea MD, who retired from UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center as the John William Pope Distinguished Professor in Cancer Research. Dr. Shea is widely respected for his clinical and research contributions that have advanced the bone marrow transplant field.

Dr. Shea received his undergraduate and medical degrees from the University of North Carolina at Chapel Hill and completed his residency training in internal medicine and fellowship in hematology and oncology at Beth Israel Hospital in Boston. He undertook additional training in bone marrow transplantation at the Dana-Farber Cancer Institute and was an instructor at Harvard Medical School before starting the bone marrow transplant program at the University of California at San Diego in 1988.

In 1992, he returned to UNC where he established the bone marrow and stem cell transplantation program. During his 27-year career he held multiple leadership posts at UNC, including medical director of the UNC Bone Marrow Transplant Program, principal investigator for the institution's grant from CALGB/ALLIANCE, associate chief of the Division of Hematology and Oncology, and associate director for the UNC Lineberger Clinical Outreach Programs.

In addition to his service to UNC, Dr. Shea has held several important roles outside the University including as Chair of the Center for International Bone Marrow Transplant Research and Vice Chair of the ALLIANCE Transplant and Leukemia Committees. He also served on multiple advisory boards, review committees, and study sections for the National Cancer Institute, the American Cancer Society, and the Leukemia and Lymphoma Society. Dr. Shea has published extensively in the areas of bone marrow transplantation and the management of patients with hematologic malignancies.

Befitting his role in holistically improving the care of patients with cancer, Dr. Shea was pivotal to the establishment of the SECU Family House, a hospitality house for patients and families staying at UNC Hospitals while undergoing prolonged care. His work in these areas was recognized by his receipt of the Order of the Longleaf Pine from Governor Roy Cooper.

Dr. Shea has been married for over 40 years to Dr. Katherine Shea and has two wonderful adult children, Meg and Joe, and one granddaughter, Izzy and a grandson, Alex. He stays busy in retirement by doing a little consulting, but mostly playing golf, taking care of a small farm in Southwest Virginia, volunteering at the SECU Family House, and participating in service projects with the East Chapel Hill Rotary Club.

THANK YOU TO OUR EXHIBITORS!

ADC THERAPEUTICS

ASTRAZENECA

BeONE MEDICINES

ELI LILLY AND COMPANY

GENENTECH

GENMAB

JAZZ PHARMACEUTICALS

MERCK & Co., Inc.

NOVARTIS INC.

PFIZER



LINEBERGER COMPREHENSIVE
CANCER CENTER

CME Information

Accreditation Statement

The School of Medicine of the University of North Carolina at Chapel Hill is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Statement

The School of Medicine of the University of North Carolina at Chapel Hill designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

Planners

This activity has been planned and implemented under the sole supervision of the Course Directors, Deborah Stephens, DO, and Kaitlin Morrison, PhD, and the planning committee, Anne Beaven, MD, and Natalie Grover, MD, in association with the UNC Office of Continuing Professional Development (CPD). CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME. Dr. Morrison has no relevant financial relationships with ineligible companies.

Dr. Stephens received consulting fees from AbbVie, AstraZeneca, BeiGene, BMS, Celgene, Genentech, Janssen, Lilly, and Pharmacyclics; and research support from AbbVie, AstraZeneca, BeiGene, Genentech, Merck, and Novartis.

Dr. Beaven received consulting fees from Vittoria Biotherapeutics (ended 12/23) and research support from Genentech.

Dr. Grover held stock in Sangamo; received consulting fees from ADC Therapeutics (ended 6/24), BMS (3/24), Caribou Biosciences (2/23), Genentech, Janssen (9/23), Kite (3/23), Novartis, Ono Pharma (12/23), Regeneron, Seagen (7/23); and research support from Affimed, BMS, Cabaletta, Poseida, and Regeneron.

These financial relationships have been mitigated; the planners have recused themselves from planning content related to the products or services offered by the companies with which they have relationships.

Speakers

For the speakers who are also planners, please see above.

Dr. Byrd held stock options in Eilean Therapeutics, Kurome, and Vincerx Pharma; received consulting fees from AbbVie, AstraZeneca, Eilean Therapeutics, Kartos, Kurome, Newave, Orange Grove Bio, Orbimed, and Vincerx Pharma; and received research support from Eilean Therapeutics, Newave, Orange Grove Bio, and Orbimed.

Dr. Dittus received research grants from AstraZeneca, Genentech, and Seagen.

Dr. Friedberg has no relevant financial relationships.

Dr. Hu received consulting fees from AbbVie (ended 2/24), ADC Therapeutics (11/24), Bristol Myers Squibb (10/24), Caribou Biosciences (2/24), Genentech (11/24), Kite (5/24), Pfizer (9/24), and Regeneron (1/24); and research support from Artiva Biotherapeutics, AstraZeneca, Caribou Biosciences, Celgene (1/24), CRISPR Therapeutics, Genentech, ImmPACT Bio, Morphosys AG, Newave, and Repare Therapeutics (10/24).

Dr. Jensen received consulting fees from Abbvie (ended 12/24) and Cardinal Health (ended 10/24).

Dr. Shadman held stock options in Koi Biotherapeutics; received speaker fees from Janssen (ended 2/23); receives consulting fees from AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lilly, Fate Therapeutics, Genentech, Genmab, Janssen, Kite Pharma, Merck, Morphosys/Incyte, and Nurix; and received research grants from AbbVie, AstraZeneca, BeiGene, Genentech, Genmab, Morphosys/Incyte, Mustang Bio, and Vincerx.

Dr. Smith has no relevant financial relationships.


All of the presenters' financial relationships have been mitigated through slide review by UNC CPD.



LINEBERGER COMPREHENSIVE
CANCER CENTER

NOTES

NOTES



LINEBERGER
COMPREHENSIVE
CANCER CENTER